What are the main challenges facing NK cell immunotherapy for treating solid tumors?
Natural killer (NK) cells are immune cells that can kill cancer cells without needing a specific antigen match, making them promising for 'off-the-shelf' therapies. However, treating solid tumors with NK cell immunotherapy is much harder than treating blood cancers. The main challenges include getting NK cells to enter the tumor, surviving the hostile environment inside the tumor, and finding targets that are present on all cancer cells.
What the research says
A key challenge is the immunosuppressive tumor microenvironment (TME). Solid tumors create a hostile environment that exhausts immune cells, including NK cells, and limits their ability to function 39. The TME is metabolically stressful, with low oxygen and nutrients, which can cause NK cells to become dysfunctional 28. Another major issue is antigen heterogeneity: solid tumors often have diverse cells that do not all express the same target, so NK cells may miss some cancer cells 910. Additionally, NK cells have difficulty infiltrating solid tumors because of physical barriers and suppressive signals 38. Finally, NK cells often have limited persistence and can become exhausted quickly, reducing their long-term effectiveness 23.
What to ask your doctor
- How does the tumor microenvironment in my specific cancer type affect the potential success of NK cell therapy?
- Are there ongoing clinical trials testing NK cell therapies for my type of solid tumor?
- What strategies are being used to improve NK cell persistence and tumor infiltration in solid tumors?
- Could combining NK cell therapy with other treatments, such as checkpoint inhibitors, be an option for me?
- How is antigen heterogeneity addressed in NK cell therapy approaches for solid tumors?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.